Intravenous-to-oral antibiotic switch therapy: A cost-effective approach

Postgraduate Medicine

Volumn 101, Issue 4, 1997, Pages

  Cunha, Burke A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEFALEXIN; CEFEPIME; CEFIXIME; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME AXETIL; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; PIPERACILLIN; SULTAMICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG COST; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0030897443     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.04.199     Document Type: Review

References (13)

1. Rodvold KA. Pharmacokinetic and pharmacodynamic considerations for antimicrobial use. Infect Med 1995;12:16-25A
2. Nightingale CH, Belliveau PP, Quintiliani R. Cost issues and considerations when choosing antimicrobial agents. Infect Dis Clin Pract 1995;273:214-9
3. Quintiliani R, Nightingale CH, Freeman CD. Pharmacokinetic and pharmacodynamic considerations in antibiotic selection, with particular attention to oral cephalosporins. Infect Dis Clin Pract 1994;3:1-7
4. Conly JM, Low DE. Intravenous to oral antimicrobial stepdown therapy: improving the quality of care and reducing costs. Can J Infect Dis 1995;6:3-5A
5. Quintiliani R, Nightingale CH. Transitional antibiotic therapy. Infect Dis Clin Pract 1994;3(3):S161-7
6. Jewesson PT. Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy. Can J Infect Dis 1995;6:11-6A
7. Ballow CH. Cost considerations in oral antibiotic therapy. Adv Ther 1995;12(4):199-206
8. Vogel F. Transitional parenteral-to-oral therapy in community-acquired pneumonia. Hosp Pract 1996;31:21-6
9. Cunha BA. Community-acquired pneumonia: cost-effective antimicrobial therapy. Postgrad Med 1996;99(1):109-10, 113-4, 117-9
10. Degelau J, Guay D, Straub K, et al. Effectiveness of oral antibiotic treatment in nursing home-acquired pneumonia. J Am Geriatr Soc 1995;43(3):245-51
11. Zuck P, Rio Y, Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother 1990;26(Suppl E):71-7
12. Gleckman RA. Oral empirical treatment of pneumonia: the challenge of choosing the best agent. Postgrad Med 1994;95(2):165-72
13. Pneumonia Study Group. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob Agents Chemother 1996;40(5):1175-9